Innovation in infertility management

Extending the application of the method would require fewer flask cycles, since the first IVF treatment would be more likely to succeed, as would the number of twin pregnancies.

In most cases, the miscarriage of the embryo during pregnancy and during flask programs is responsible for the chromosomal aberration of the embryo.
Over 37 years of age, approximately 70% of natural and artificial embryos conceived and over 40 years of age carry 80-100% of these embryos (Hassold & Hunt, 2001). In these cases, the pregnancy usually results in a miscarriage or the birth of a newborn with a serious genetic disorder. Most of the time, however, the embryo carrying the chromosomal abnormality does not adhere to the uterus, so the use of this disclosed PGD-A method in flask treatment is of paramount importance.

By genetic testing against abortions

Miscarriages, as well as fetuses conceived by severe genetic abnormalities, can also be a tremendous psychological burden for the family in the event of a natural pregnancy. It is natural for parents to perform countless tests to make sure they are rool healthy. And for couples who participate in the Flask Babylon Program (IVF), the need to reduce the risk of complications is even greater, as they often go through a series of physical and mental strain.
However, in our country, participants in the flask program may not be confident that a healthy (free of chromosome aberration) embryo will be implanted in the IVF program. For the detection of these disorders is a single method, PGD-A (Preimplantation Genetics Diagnosis Aneuploidia Screening) or PGS (Preimplantation Genetic Screening).
It is widespread practice to test the fetus in the flask program before using the PGD-A method. Genetic sampling from a 3 or 5 day pre-embryo can be performed with great certainty, without embryo malfunctioning, and its clinical utility unequivocally demonstrates that in a series of studies, 10 embryos carry an average of 7-8 embryos.

A beautiful embryo may not be viable

"The essence of the problem is that it is not possible to determine the embryo's viability by external (morphological) signals. . in practice, it lбtjuk that there цsszefьggйs the embriу "szйpsйge" йs the йletkйpessйge kцzцtt. Ezйrt PGD the vizsgбlat nйlkьl kivбlasztott embriуk often unfortunately unnecessarily kerьlnek visszahelyezйsre the anyamйhbe. the kцvetkezmйny the hosszъ vбrakozбs utбni negatнv terhessйgi test, the lйtrejцtt terhessйg loss of miscarriage, or the tragic life situation where a couple has to decide whether to have a seriously ill fetus. The physical and mental strain that comes with it is serious, "he said. Dr. Attila Vereczkey a medical and endoscopic specialist, medical director of the Versys Clinics Human Reproduction Institute. The Institute is the first and only PGD-A in Hungary to use the PGD-A test in accordance with effective prescriptions, except for advanced maternal age and many times after failed IVF treatment.
With the help of the PGD-A procedure, which has been used in the field for a long time, doctors have been able to select embryos that have had a viral or serious genetic abnormality in the womb during flask programs. Geneticist Dr. Alan Tornhill said that technology that has been introduced in several countries to date has employed more than 500,000 embryos worldwide to increase the effectiveness of the IVF program.

There is no legal or ethical barrier to PGD-A application in IVF

In our country, the application of PGD-A technology has been a cross-industry issue for many years. Unfortunately, there have been many misunderstandings, even in medical circles, he explained. Professor Endre Czeizel, doctor of medicine. However, due to well-established professional standards, it was confirmed by a three-year examination of the BNTSZ, and in the end of November 2014 it was justified to apply the method in Hungary.

Dr. Attila Vereczkey, Dr. Alan Tornhill, Dr. Endre Czeizel

Professor Czeizel According to the eljбrбs alkalmazбsбnak ethical vitatottsбga well founded, since the vizsgбlat йpp so tekinthetх "genetic szelekciуnak" like when you have already recognized lйtrejцtt terhessйg sorбn idхben fetal rendellenessйg alapjбn the elй the fбjdalmas kйrdйs elй бllнtjбk the szьlхket to vбllaljбk whether genetically sйrьlt fetus vilбgrahozatalбt . The PGD-A assay used in flask programs is intended to minimize the development of such severely stressed living conditions, since the embryo showing no chromosomal aberration is well-tolerated and ill for a period of about 9 months.
Hopefully, with the growing recognition of the process, the method and the concept of PGD-A will not be washed away as much as the image of the embryo will be impressed upon. Hungarian difficult-to-conceive couples have better chances of having a baby, and can be protected from many painful experiences with PGD-A's wide-ranging application.

Economic aspects of the application of the PGD-A method

Extending the application of the method would require fewer flask cycles for Hungarian difficult-to-conceive couples, as the first IVF treatment would be more likely to be successful, thus also putting a strain on the physical and physical strain.
IVF treatments may result in more frequent multiple pregnancies. In the PGD-A test, the number of embryos placed can be reduced while maintaining the pregnancy rate. Thus, the rate of twin pregnancies and related events (eg, premature birth) are significantly reduced, which could mean significant savings for public finances.
The effectiveness of the method is also proven by the efficacy data of a clinic that is unique to the procedure in Hungary. In 2014, the Pregnancy Rate at Versys Clinics Human Reproduction Institute was 55.38%, regardless of age, independently of PGD-A, which is significantly higher than in Hungary. Pregnancy rates for patients with good prognosis in the period 2013-2014 were 74.29%. Patients treated in 2014 had an average age of 39.4 years.